Menu Search
Equities

Towa Pharmaceutical Co Ltd

TWAPF:PKL

Towa Pharmaceutical Co Ltd

Actions
  • Price (USD)24.35
  • Today's Change0.00 / 0.00%
  • Shares traded26.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Aug 02 2024 21:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Towa Pharmaceutical Co Ltd grew revenues 9.13% from 208.86bn to 227.93bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 634.80% net income growth from 2.20bn to 16.17bn.
Gross margin35.90%
Net profit margin7.17%
Operating margin10.19%
Return on assets4.00%
Return on equity11.02%
Return on investment4.91%
More ▼

Cash flow in JPYView more

In 2024, Towa Pharmaceutical Co Ltd increased its cash reserves by 22.23%, or 5.39bn. Cash Flow from Financing totalled 35.41bn or 15.53% of revenues. In addition the company generated 8.21bn in cash from operations while cash used for investing totalled 40.39bn.
Cash flow per share716.74
Price/Cash flow per share4.32
Book value per share3,311.49
Tangible book value per share2,297.49
More ▼

Balance sheet in JPYView more

Towa Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 56.66%, a lower figure than the previous year's 116.55%.
Current ratio2.94
Quick ratio1.62
Total debt/total equity1.31
Total debt/total capital0.5666
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)2.21%
Div growth rate (5 year)10.86%
Payout ratio (TTM)17.45%
EPS growth(5 years)5.34
EPS (TTM) vs
TTM 1 year ago		204.51
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.